Toronto, Ontario–(Newsfile Corp. – October 22, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology
MindBio Therapeutics Corp. reported that the final milestone in the Company’s Phase 2A Microdosing Depression Clinical Trial, the 6-month post treatment milestone measuring the “severity
A team of scientists has discovered surprising connections among gene activity, genome packing, and genome-wide motions, revealing aspects of the genome’s organization that directly affect
Exposure to higher levels of air pollution as a baby is linked to having a peanut allergy throughout childhood, according to a new study.
Black, Hispanic, and American Indian/Alaska Native (AI/AN) adults in the United States are more likely to be hospitalized with flu, as well as less likely
Research shows individuals with anosmia have altered breathing patterns, linking smell loss to health issues and highlighting olfaction’s role in respiration.
The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in
Genevant LNP technology will provide a vehicle for Editas’ CRISPR/Cas12a gene therapy. Credit: ART-ur / Shutterstock. Editas Medicine and Genevant Sciences will collaborate to develop
Good morning! There are two impending deadlines weighing on my mind this week: We’ve got exactly two weeks until the presidential election, and 12 days